Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Search
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Expertise in microbial | Bioxcellence | Boehringer Ingelheim
Leverage BIOXcellence's expertise in microbial production, providing high-quality, reliable biopharmaceutical manufacturing solutions for your business.
Global Top Employer 2023
Global Top Employer 2023
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Our Asthma Products
Our Asthma Products
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
NeO - smart and sustainable vaccines
The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
Investing in our people University of Medicine Excellence
Almost one thousand of our employees have graduated from a program developed together with Harvard Medical School’s Executive Education.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
BI X colleague about working with purpose
Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim
Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Scouting for digital innovation
Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Award winning employers
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".